Yamazawa (9993) · RiskDropped
Downward Pressure on Dispensing Profits from Drug Price Revisions
First written in FY2017-Q1. 1 of 4 entries say "Reframed", first in FY2017-Q2. Latest entry: FY2022.
4entries
7years
0from disclosures
How it moved
Same theme, other companies
Lower revenue and profit in the dispensing pharmacy business due to drug price revisions and procurement costs, among other factorsA theme 7 companies write about · 7 as a headwind · 0 as a tailwind
0 other companies' latest entry also says "Dropped".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2022DroppedAnnual reportThe downward pressure on profits from previous drug price and dispensing fee revisions is not specifically described as a major risk in this filing.
- FY2017WorsenedAnnual report
「In the dispensing business, there were downward pressure factors, including drug price reductions accompanying the revision of medical fees and a substantial decline in sales of products related to hepatitis C treatments,」
In addition to the previous downward pressure from drug price and dispensing fee revisions, the company specifies drug price reductions and the substantial decline in sales of products related to hepatitis C treatments as downward pressure factors. - FY2017-Q2ReframedAnnual report
「At dispensing pharmacies, a revision to dispensing fees was implemented in April 2016 and has been a factor behind the decline in profit,」
Although the wording changed from “drug price revision” to “dispensing fee revision,” the same subject is identified as a factor behind the decline in dispensing profits. - FY2017-Q1First statedAnnual report
「A drug price revision was implemented in April 2016 and has been a factor behind the decline in profit.」
The April 2016 drug price revision is specifically cited as a factor behind the decline in pharmacy profits.